Table 2. Clinical parameters of patients with testosterone deficiency syndrome who received TRT (n=54).
| Parameter | Baseline | After TRT | p-value |
|---|---|---|---|
| BMI (kg/m2) | 26.2±2.0 | 26.3±2.1 | 0.320 |
| PSA (ng/mL) | 0.8±1.3 | 1.1±1.2 | 0.113 |
| Prostate volume (mL) | 23.8±8.8 | 25.5±7.4 | 0.546 |
| Hemoglobin (g/dL) | 12.7±1.1 | 13.5±1.4 | 0.071 |
| Hematocrit (%) | 36.8±3.4 | 39.6±5.1 | 0.065 |
| Qmax (mL/s) | 14.2±5.6 | 17.5±4.6 | 0.076 |
| PVR (mL) | 14.9±10.6 | 12.5±8.7 | 0.093 |
| Total testosterone (ng/mL) | 2.5±0.6 | 6.8±3.0 | 0.010 |
| IIEF-5 score | 20.7±4.8 | 23.8±3.6 | 0.031 |
| AMS score | 41.4±9.7 | 28.8±3.6 | 0.047 |
| BDI score | 26.6±4.2 | 20.8±7.3 | 0.033 |
| K-MMSE score | 24.8±4.4 | 25.8±3.8 | 0.094 |
Values are presented as mean±standard deviation.
TRT: testosterone replacement therapy, BMI: body mass index, PSA: prostate-specific antigen, Qmax: maximal urinary flow rate, PVR: postvoid residual volume, IIEF-5: 5-item version of the International Index of Erectile Function questionnaire, AMS: Aging Males' Symptoms, BDI: Beck Depression Inventory, K-MMSE: Korean Mini-Mental State Examination.